Abbott Settles $385 Million Claims Over Contaminated Infant Formula Supply

In a remarkable turn of events, Abbott Laboratories has reached a multistate settlement of nearly $385 million to resolve allegations that it supplied infant formula produced under unsafe conditions to federally funded nutrition assistance programs, including Medicaid and WIC (Women, Infants, and Children). Announced in September 2026 by the Attorneys General of Oregon and Massachusetts, the settlements come in response to serious claims regarding the health and safety of products that countless families rely on for their infants' nutrition. The implications of these settlements are profound, particularly in regards to procurement practices within health-related government programs. This case addresses not only the specific failures of Abbott but also serves as a cautionary tale for all suppliers in the nutritional products sector engaged with government contracts.

Over the past several years, significant allegations have been leveled against Abbott regarding its manufacturing processes, particularly at its facilities located in Sturgis, Michigan, and Casa Grande, Arizona. Investigations conducted by the U.S. Department of Agriculture and various state agencies revealed severe safety compliance failures. Between January 2018 and December 2022, Abbott purportedly failed to maintain essential manufacturing equipment and control potential contamination risks, putting infants at risk of exposure to harmful microorganisms. Furthermore, during inspections by the FDA in 2019 and 2022, it was discovered that Abbott had withheld test results indicating contamination at the Sturgis facility.

The impact of these settlements is far-reaching and underscores the critical need for robust regulatory oversight in the procurement processes for products that affect vulnerable populations. The settlements not only require Abbott to pay $348.7 million to the federal government and $35.5 million to all participating states, but they also emphasize the urgency for procurement professionals within government and health sectors to ensure their suppliers have stringent safety protocols in place. The ramifications for non-compliance could not only threaten public health but could also lead to significant financial repercussions.

Furthermore, the settlements send a strong message regarding accountability. As stated by Oregon Attorney General Dan Rayfield, "Abbott Laboratories broke that trust and used taxpayer dollars to do it. We will hold companies accountable when they put people— in this case, babies—at risk." This highlighted need for oversight may result in increased scrutiny for companies supplying products to government health programs.

Procurement professionals should be aware that when contracting with suppliers of essential nutritional products, there is a heightened level of regulatory risk. Governments are entering into contracts that sharply prioritize quality assurance and compliance monitoring to prevent situations like the one Abbott faced. In light of this settlement, vendors in the nutritional and health sectors should urgently reassess their compliance protocols.

There is a clear expectation for all companies involved in similar supply chains to prioritize safe manufacturing practices and transparency in their operations. States are likely to increase efforts towards compliance audits and investigations into the health products supplied through government contracts, making robust quality management systems imperative. Overall, this event serves as a reminder that procurement practices are not just about cost, but are intricately linked to public trust and safety. It remains essential for procurement teams to work diligently with vendors that uphold high ethical and safety standards to protect public health and adhere to government regulations.